Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04068753 · ClinicalTrials.gov registry record · Phase 2
Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer
A Phase 2 study of Recurrent Cervix Cancer and Progressive Cervix Cancer, sponsored by University of Oklahoma.
- Active
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 4
- Study locations
NCT04068753 is a Phase 2 study of Recurrent Cervix Cancer and Progressive Cervix Cancer that is active but no longer recruiting, run by University of Oklahoma. The registered enrollment target is 66 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT04068753, a Phase 2 study of Recurrent Cervix Cancer and Progressive Cervix Cancer, is active but no longer recruiting, sponsored by University of Oklahoma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this research study is to test the safety of Niraparib and dostarlimab as a combination treatment and see what effects (good and bad) this combination treatment has on patients with recurrent or progressive cervix cancer.
Conditions Studied
Interventions
- DRUG Niraparib
- DRUG dostarlimab
Study Locations (4)
Indiana
- Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Louisiana
- Louisiana State University Health Science Center - New Orleans
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Virginia
- University of Virginia Cancer Center - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2020-02-26 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04068753
The ClinicalTrials.gov registry entry for NCT04068753 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Cervix Cancer appearing as the primary indexed condition, and to 2 interventions - of which Niraparib is the first listed.
NCT04068753 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Indiana, Louisiana, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT04068753 about?
NCT04068753 is a clinical study titled "Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer". The purpose of this research study is to test the safety of Niraparib and dostarlimab as a combination treatment and see what effects (good and bad) this combination treatment has on patients with recurrent or progressive cervix cancer.
What is the current status of trial NCT04068753?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2020-02-26. Estimated completion is 2027-07.
What conditions does trial NCT04068753 study?
This clinical trial studies the following conditions: Recurrent Cervix Cancer, Progressive Cervix Cancer.
What interventions are being tested in trial NCT04068753?
The interventions under investigation include: Niraparib (DRUG), dostarlimab (DRUG).
Who is sponsoring clinical trial NCT04068753?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04068753 being conducted?
This trial has 4 study locations across Indiana, Louisiana, Oklahoma, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.